SchistoFLRFamide (PDVDHVFLRFamide) is one of the endogenous FMRFamide-like neuropeptides found in the nervous system of the locust Schistocerca gregaria (Robb et al. 1989; Robb and Evans, 1990). FMRFamide-like neuropeptides modulate the actions of a wide variety of both skeletal and visceral muscles in insects (Evans and Myers, 1986a; Schoofs et al. 1993b) and have been suggested to act both as circulatory hormones and as locally released neurotransmitters (see discussion in Robb and Evans, 1990).

SchistoFLRFamide was originally isolated from the nervous system of Schistocerca gregaria using a combination of radioimmunoassay, HPLC and bioassay (Robb et al. 1989; Robb and Evans, 1990). Preliminary data indicate that it inhibits spontaneous contractions of the locust heart and has a complex dose-dependent effect upon contractions induced in the extensor tibiae muscle by stimulation of the slow excitatory motoneurone (Robb et al. 1989). In addition, SchistoFLRFamide has recently been shown to decrease the amplitude and frequency of myogenic contractions and to reduce basal tension in locust oviduct muscle (Peeff et al. 1993).

The present paper provides a more detailed account of the modulatory effect of SchistoFLRFamide on heart and skeletal muscle in the locust Schistocerca gregaria. The effects of the synthetic peptide were measured on the semi-isolated locust heart (Cuthbert and Evans, 1989). The results are expressed as the percentage change in the amplitude of the heartbeat and its frequency with respect to measurements obtained immediately before the application of the peptide. Measurements of heart rate and contraction amplitude were averaged over a 1 min period, starting (a) 1 min before the beginning of the peptide pulse, (b) 1 min after the start of the peptide pulse, (c) 4 min after the start of the peptide pulse and (d) 1 min after the end of the peptide pulse. The bioactivity of synthetic SchistoFLRFamide was also assayed on another well-defined FMRFamide bioassay preparation from the locust. The effects were measured on the twitch tension evoked in the extensor tibiae muscle of the hindleg of the locust by stimulating the slow excitatory motoneurone to this muscle at 1 Hz (Evans and Myers, 1986b). The results are expressed as the maximal effects on the twitch amplitude.

SchistoFLRFamide had a potent dose-dependent cardioinhibitory effect on both the amplitude and frequency of spontaneous contractions in the semi-isolated locust heart, with a threshold for an observable effect occurring between 10−9 and 10−8 mol l−1 (Fig. 1). At low concentrations (10−8 mol l−1) SchistoFLRFamide had a slight cardioinhibitory effect, which lasted only while the heart was exposed to the peptide, and the heart rate returned to pre-exposure levels within 2 min of peptide removal (Figs 1Aiii, 2A). At higher concentrations (10−8 to 10−5 mol l−1), SchistoFLRFamide had potent cardioinhibitory effects on both the amplitude and frequency of heart contraction (Figs 1, 2B). These effects were long-lasting and in many preparations were still visible more than 2 min after peptide removal from the superfusate (Fig. 1Aiii, Biii). Fig. 2B shows a preparation in which a 5 min pulse of 10−7 mol l−1 SchistoFLRFamide initially reduced both the frequency and amplitude of spontaneous contractions. The effect on the frequency of spontaneous contractions lasted for about 2 min after the removal of the peptide from the superfusate but, in this preparation, the contraction amplitude returned to control levels before the end of the pulse and was even potentiated by 35 s after the end of the pulse. In general, the effects of the peptide were observed for longer in the wash-out period when higher concentrations were applied (see Robb et al. 1989). At 10−6 mol l−1 SchistoFLRFamide these effects were more pronounced (see Robb et al. 1989). Heart contractions were rapidly abolished, an effect that persisted for several minutes after the peptide had been removed from the superfusate. As heartbeat frequency began to recover during the wash-out, contraction amplitude was always potentiated for several minutes. These potentiating effects of high doses of SchistoFLRFamide are not visible in the dose–response curves (Fig. 1); they did not occur until several minutes after the peptide had been removed from the superfusate.

Fig. 1.

Dose–response curves for the actions of synthetic SchistoFLRFamide on (A) the contraction amplitude and (B) the contraction frequency of the semi-isolated locust heart preparation during (i) the second minute of a 5 min exposure to the peptide, (ii) the final minute of a 5 min exposure to the peptide and (iii) the second minute after the end of a 5 min pulse of this peptide. The error bars represent the standard error of the mean, N=3. The frequency and amplitude of spontaneous heart contractions were measured almost isometrically by attaching the heart to a force transducer (see Cuthbert and Evans, 1989). The drug was superfused over the preparation in isotonic saline at a rate of 1 ml min−1 and each heart was maintained in a volume of 200 μl of saline.

Fig. 1.

Dose–response curves for the actions of synthetic SchistoFLRFamide on (A) the contraction amplitude and (B) the contraction frequency of the semi-isolated locust heart preparation during (i) the second minute of a 5 min exposure to the peptide, (ii) the final minute of a 5 min exposure to the peptide and (iii) the second minute after the end of a 5 min pulse of this peptide. The error bars represent the standard error of the mean, N=3. The frequency and amplitude of spontaneous heart contractions were measured almost isometrically by attaching the heart to a force transducer (see Cuthbert and Evans, 1989). The drug was superfused over the preparation in isotonic saline at a rate of 1 ml min−1 and each heart was maintained in a volume of 200 μl of saline.

Fig. 2.

The effect of 5 min pulses of various concentrations of synthetic SchistoFLRFamide (black bars) on the spontaneous contractions of the semi-isolated locust heart preparation. (A) The effect of a 5 min pulse of 10−8 mol l−1 SchistoFLRFamide; (B) the effect of a 5 min pulse of 10−7 mol l−1 SchistoFLRFamide.

Fig. 2.

The effect of 5 min pulses of various concentrations of synthetic SchistoFLRFamide (black bars) on the spontaneous contractions of the semi-isolated locust heart preparation. (A) The effect of a 5 min pulse of 10−8 mol l−1 SchistoFLRFamide; (B) the effect of a 5 min pulse of 10−7 mol l−1 SchistoFLRFamide.

SchistoFLRFamide also produced a complex dose-dependent pattern of potentiation and inhibition on both the amplitude and relaxation rate of slow-motoneurone-induced twitch tension in the extensor tibiae muscle of the locust hindleg. At concentrations between 10−12 and 10−8 mol l−1, SchistoFLRFamide produced a small but variable increase of 10–20% in the amplitude of twitch tension. At higher concentrations, between 10−7 and 10−5 mol l−1, the amplitude responses were complex and varied between preparations. In most preparations (six out of seven) the responses were excitatory (e.g. Fig. 3i), but in one preparation the amplitude of twitch tension was reduced at all concentrations tested. Many of the excitatory responses were biphasic, with an initial transient inhibition preceding the main excitatory response. Fig. 3ii shows a preparation in which a biphasic response was induced at 10−6 mol l−1 but in which exposure to 10−5 mol l−1 peptide produced purely a large excitation, whilst Fig. 3iii shows a preparation in which excitation was produced at 10−8 mol l−1, inhibition at 10−7 mol l−1 and 10−6 mol l−1 and a biphasic effect at 10−5 mol l−1. Possible reasons for the different degrees of inhibition and excitation shown by individual preparations are currently being investigated. Similar biphasic results were obtained for the effect of SchistoFLRFamide on the relaxation rate of slow-motoneurone-induced twitch tension (data not shown).

Fig. 3.

Typical examples of the effects of 5 min pulses of various concentrations of SchistoFLRFamide on the amplitude of twitch tension induced in the hindleg extensor tibiae muscle by stimulation of the slow motor neurone to this muscle at 1 Hz in three different preparations (i–iii). (A) The effect of a 10−8 mol l−1 pulse. (B) The effect of a 10−7 mol l−1 pulse. (C) The effect of a 10−6 mol l−1 pulse. (D) The effect of a 10−5 mol l−1 pulse. Preparation i gave purely excitatory responses to all concentrations of peptide above threshold, whilst preparation ii gave excitatory responses at all concentrations above threshold except for the 10−6 mol l−1 pulse, which produced a biphasic effect with a transient inhibition preceding the main excitatory effect. In contrast, preparation iii produced an excitatory response to the 10−8 mol l−1 pulse, an inhibitory responses to the 10−7 mol l−1 and 10−6 mol l−1 pulses and a biphasic effect in response to the 10−5 mol l−1 pulse. The trace shown for preparation ii at 10−6 mol −1 has been modified from Robb et al. (1989).

Fig. 3.

Typical examples of the effects of 5 min pulses of various concentrations of SchistoFLRFamide on the amplitude of twitch tension induced in the hindleg extensor tibiae muscle by stimulation of the slow motor neurone to this muscle at 1 Hz in three different preparations (i–iii). (A) The effect of a 10−8 mol l−1 pulse. (B) The effect of a 10−7 mol l−1 pulse. (C) The effect of a 10−6 mol l−1 pulse. (D) The effect of a 10−5 mol l−1 pulse. Preparation i gave purely excitatory responses to all concentrations of peptide above threshold, whilst preparation ii gave excitatory responses at all concentrations above threshold except for the 10−6 mol l−1 pulse, which produced a biphasic effect with a transient inhibition preceding the main excitatory effect. In contrast, preparation iii produced an excitatory response to the 10−8 mol l−1 pulse, an inhibitory responses to the 10−7 mol l−1 and 10−6 mol l−1 pulses and a biphasic effect in response to the 10−5 mol l−1 pulse. The trace shown for preparation ii at 10−6 mol −1 has been modified from Robb et al. (1989).

Previous physiological investigations have provided evidence for the existence of at least two receptors for FMRFamide-like peptides in locusts, one producing excitation and the other inhibition in a number of preparations, including the extensor tibiae muscle of the hindleg (Evans and Myers, 1986a,b; Cuthbert and Evans, 1989), the heart (Cuthbert and Evans, 1989) and the oviducts (Peeff et al. 1993). Concentration-dependent biphasic effects of FMRFamide have also been reported in studies on hearts from a number of bivalve molluscs (Painter and Greenberg, 1982). Evidence has also been presented for the existence of multiple receptor types for members of this peptide family on molluscan neurones (Cottrell et al. 1984; Ruben et al. 1986; Cottrell and Davies, 1987), skeletal muscle (Cottrell et al. 1983) and heart (Payza, 1987). In the present paper, the most likely explanation for our results with SchistoFLRFamide is that this neuropeptide is capable of activating both excitatory and inhibitory subtypes of receptors in both the locust heart and extensor tibiae muscle preparations. However, in the absence of specific antagonists for these receptors, it is not possible to rule out a mechanism whereby the native peptide is acting on only a single class of receptors, whose effects vary according to the level of receptor activation. This explanation seems to be unlikely, however, since the closely related neuropeptide leucomyosuppressin, in which a single N-terminal amino acid, pyroglutamate, is substituted for the proline of SchistoFLRFamide, interacts exclusively with the inhibitory subclass of FMRFamide-like receptors (Evans and Myers, 1986a,b; Cuthbert and Evans, 1989). The exact responses obtained by the application of SchistoFLRFamide in these systems depended both on the concentration of the peptide used and on the response characteristics of the individual preparation. Thus, a detailed characterization of the pharmacology and mode of action of SchistoFLRFamide in these tissues awaits either the development of specific antagonists for the receptor subtypes or their cloning.

Cottrell
,
G. A.
and
Davies
,
N. W.
(
1987
).
Multiple receptor sites for a molluscan peptide (FMRFamide) and related peptides of Helix
.
J. Physiol., Lond.
382
,
51
68
.
Cottrell
,
G. A.
,
Davies
,
N. W.
and
Green
,
K. A.
(
1984
).
Multiple actions of a molluscan cardioexcitatory neuropeptide and related peptides on identified Helix neurones
.
J. Physiol., Lond.
356
,
315
333
.
Cottrell
,
G. A.
,
Greenberg
,
M. J.
and
Price
,
D. A.
(
1983
).
Differential effects of a molluscan neuropeptide FMRFamide and the related met-enkephalin derivative YGGFMRFamide on the Helix tentacle retractor muscle
.
Comp. Biochem. Physiol.
75C
,
373
375
.
Cuthbert
,
B. A.
and
Evans
,
P. D.
(
1989
).
A comparison of the effects of FMRFamide-like peptides on locust heart and skeletal muscle
.
J. exp. Biol.
144
,
395
415
.
Elia
,
A. J.
,
Tebrugge
,
V. A.
and
Orchard
,
I.
(
1993
).
The pulsatile appearance of FMRFamide-related peptides in the haemolymph and loss of FMRFamide-like immunoreactivity from neurohaemal areas of Rhodnius prolixus following a blood meal
.
J. Insect Biol.
39
,
459
469
.
Evans
,
P. D.
and
Myers
,
C. M.
(
1986a
).
Peptidergic and aminergic modulation of insect skeletal muscle
.
J. exp. Biol.
124
,
143
176
.
Evans
,
P. D.
and
Myers
,
C. M.
(
1986b
).
The modulatory actions of FMRFamide and related peptides on locust skeletal muscle
.
J. exp. Biol.
126
,
403
422
.
Fonagy
,
A.
,
Schoofs
,
L.
,
Proost
,
P.
,
Vandamme
,
J.
,
Bueds
,
H.
and
Deloof
,
A.
(
1992
).
Isolation, primary structure and synthesis of neomyosuppressin, a myoinhibiting neuropeptide from the grey fleshfly, Neobellieria bullata
.
Comp. Biochem. Physiol.
102C
,
239
245
.
Holman
,
G. M.
,
Cook
,
B. J.
and
Nachman
,
R. J.
(
1986
).
Isolation, primary structure and synthesis of leucomyosuppresion, an insect neuropeptide that inhibits spontaneous contractions of the cockroach hindgut
.
Comp. Biochem. Physiol.
85C
,
329
333
.
Kingan
,
T. G.
,
Teplow
,
D. B.
,
Phillips
,
J. M.
,
Riehm
,
J. P.
,
Rao
,
K. R.
,
Hildebrand
,
J. G.
,
Homberg
,
U.
,
Kammer
,
A. E.
,
Jardine
,
I.
,
Griffin
,
P. R.
and
Hunt
,
D. F.
(
1990
).
A new peptide in the FMRFamide family isolated from the CNS of the hawkmoth, Manduca sexta
.
Peptides
11
,
849
856
.
Nichols
,
R.
(
1992
).
Isolation and structural characterization of Drosophila TDVDHVFLRFamide and FMRFamide-containing neural peptides
.
J. molec. Neurosci.
3
,
213
218
.
Painter
,
S. D.
and
Greenberg
,
M. J.
(
1982
).
A survey of the responses of bivalve hearts to the molluscan neuropeptide FMRFamide and to 5-hydroxytryptamine
.
Biol. Bull. mar. biol. Lab., Woods Hole
162
,
311
322
.
Payza
,
K.
(
1987
).
FMRFamide receptors in Helix aspersa
.
Peptides
8
,
1065
1074
.
Peeff
,
N. M.
,
Orchard
,
I.
and
Lange
,
A. B.
(
1993
).
The effects of FMRFamide-related peptides on an insect (Locusta migratoria) visceral muscle
.
J. Insect Physiol.
39
,
207
215
.
Robb
,
S.
and
Evans
,
P. D.
(
1990
).
FMRFamide-like peptides in the locust: distribution, partial characterisation and bioactivity
.
J. exp. Biol.
149
,
335
360
.
Robb
,
S.
,
Packman
,
L. C.
and
Evans
,
P. D.
(
1989
).
Isolation, primary structure and bioactivity of SchistoFLRFamide, a FMRFamide-like neuropeptide from the locust, Schistocerca gregaria
.
Biochem. biophys. Res. Commun.
160
,
850
856
.
Ruben
,
P.
,
Johnson
,
J. W.
and
Thompson
,
S.
(
1986
).
Analysis of FMRFamide effects on Aplysia bursting neurones
.
J. Neurosci.
6
,
252
259
.
Schoofs
,
L.
,
Holman
,
G. M.
,
Paemen
,
L.
,
Veelaert
,
D.
,
Amelineky
,
M.
and
Deloof
,
A.
(
1993a
).
Isolation, identification and synthesis of PDVDHVFLRFamide (SchistoFLRFamide) in Locusta migratoria and its association with the male accessory glands, the salivary glands, the heart and the oviduct
.
Peptides
14
,
409
421
.
Schoofs
,
L.
,
Vanden Broeck
,
J.
and
De Loof
,
A.
(
1993b
).
The myotropic peptides of Locusta migratoria: Structures, distribution, functions and receptors
.
Insect Biochem. molec. Biol.
23
,
859
881
.